Is RBOT or PAVM more profitable?

Vicarious Surgical has a net margin of 0.00% compared to PAVmed's net margin of -21,914.12%. PAVmed's return on equity of -146.19% beat Vicarious Surgical's return on equity. Company Net Margins Return on Equity Return on Assets Vicarious Surgical N/A -184.13% -112.50% PAVmed -21,914.12% -146.19% -18.39%

Does the media favor RBOT or PAVM?

In the previous week, PAVmed had 1 more articles in the media than Vicarious Surgical. MarketBeat recorded 2 mentions for PAVmed and 1 mentions for Vicarious Surgical. PAVmed's average media sentiment score of 1.31 beat Vicarious Surgical's score of 0.00 indicating that PAVmed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vicarious Surgical 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral PAVmed 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer RBOT or CLGN?

In the previous week, CollPlant Biotechnologies had 2 more articles in the media than Vicarious Surgical. MarketBeat recorded 3 mentions for CollPlant Biotechnologies and 1 mentions for Vicarious Surgical. CollPlant Biotechnologies' average media sentiment score of 0.96 beat Vicarious Surgical's score of 0.00 indicating that CollPlant Biotechnologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vicarious Surgical 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CollPlant Biotechnologies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer LUCY or RBOT?

Vicarious Surgical has a consensus target price of $7.00, indicating a potential upside of 4,017.65%. Given Vicarious Surgical's stronger consensus rating and higher possible upside, analysts plainly believe Vicarious Surgical is more favorable than Innovative Eyewear. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Innovative Eyewear 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Vicarious Surgical 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Do analysts rate RBOT or FEED?

Vicarious Surgical currently has a consensus target price of $7.00, indicating a potential upside of 4,017.65%. Given Vicarious Surgical's stronger consensus rating and higher possible upside, research analysts clearly believe Vicarious Surgical is more favorable than Nanovibronix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vicarious Surgical 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Nanovibronix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer BJDX or RBOT?

Vicarious Surgical has a consensus price target of $7.00, suggesting a potential upside of 4,017.65%. Given Vicarious Surgical's stronger consensus rating and higher possible upside, analysts plainly believe Vicarious Surgical is more favorable than Bluejay Diagnostics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bluejay Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Vicarious Surgical 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Which has better earnings and valuation, BJDX or RBOT?

Bluejay Diagnostics is trading at a lower price-to-earnings ratio than Vicarious Surgical, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bluejay Diagnostics N/A N/A -$6.85M -$11.63 N/A Vicarious Surgical N/A N/A -$63.22M -$6.69 N/A

Is BJDX or RBOT more profitable?

Bluejay Diagnostics' return on equity of -144.27% beat Vicarious Surgical's return on equity. Company Net Margins Return on Equity Return on Assets Bluejay Diagnostics N/A -144.27% -115.00% Vicarious Surgical N/A -184.13% -112.50%

Vicarious Surgical (RBOT) Competitors

$0.17 +0.03 (+18.06%)

As of 10:55 AM Eastern

Compare

RBOT vs. PAVM, CLGN, LUCY, FEED, and BJDX

Should you buy Vicarious Surgical stock or one of its competitors? MarketBeat compares Vicarious Surgical with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Vicarious Surgical include PAVmed (PAVM), CollPlant Biotechnologies (CLGN), Innovative Eyewear (LUCY), Nanovibronix (FEED), and Bluejay Diagnostics (BJDX). These companies are all part of the "medical equipment" industry.

How does Vicarious Surgical compare to PAVmed?

Vicarious Surgical (NYSE:RBOT) and PAVmed (NASDAQ:PAVM) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership, media sentiment and analyst recommendations.

Vicarious Surgical has a beta of 1.75, indicating that its share price is 75% more volatile than the broader market. Comparatively, PAVmed has a beta of 0.58, indicating that its share price is 42% less volatile than the broader market.

In the previous week, PAVmed had 1 more articles in the media than Vicarious Surgical. MarketBeat recorded 2 mentions for PAVmed and 1 mentions for Vicarious Surgical. PAVmed's average media sentiment score of 1.31 beat Vicarious Surgical's score of 0.00 indicating that PAVmed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vicarious Surgical	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
PAVmed	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

47.3% of Vicarious Surgical shares are owned by institutional investors. Comparatively, 19.9% of PAVmed shares are owned by institutional investors. 11.1% of Vicarious Surgical shares are owned by company insiders. Comparatively, 13.4% of PAVmed shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Vicarious Surgical has a net margin of 0.00% compared to PAVmed's net margin of -21,914.12%. PAVmed's return on equity of -146.19% beat Vicarious Surgical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vicarious Surgical	N/A	-184.13%	-112.50%
PAVmed	-21,914.12%	-146.19%	-18.39%

PAVmed has higher revenue and earnings than Vicarious Surgical. PAVmed is trading at a lower price-to-earnings ratio than Vicarious Surgical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vicarious Surgical	N/A	N/A	-$63.22M	-$6.69	N/A
PAVmed	$70K	89.14	$400K	-$37.40	N/A

Vicarious Surgical presently has a consensus price target of $7.00, indicating a potential upside of 4,017.65%. PAVmed has a consensus price target of $56.00, indicating a potential upside of 797.44%. Given Vicarious Surgical's higher probable upside, analysts clearly believe Vicarious Surgical is more favorable than PAVmed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vicarious Surgical	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
PAVmed	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

PAVmed beats Vicarious Surgical on 9 of the 15 factors compared between the two stocks.

How does Vicarious Surgical compare to CollPlant Biotechnologies?

Vicarious Surgical (NYSE:RBOT) and CollPlant Biotechnologies (NASDAQ:CLGN) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and valuation.

CollPlant Biotechnologies has higher revenue and earnings than Vicarious Surgical. CollPlant Biotechnologies is trading at a lower price-to-earnings ratio than Vicarious Surgical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vicarious Surgical	N/A	N/A	-$63.22M	-$6.69	N/A
CollPlant Biotechnologies	$2.37M	2.23	-$11.49M	-$1.45	N/A

Vicarious Surgical has a beta of 1.75, suggesting that its share price is 75% more volatile than the broader market. Comparatively, CollPlant Biotechnologies has a beta of 1.57, suggesting that its share price is 57% more volatile than the broader market.

In the previous week, CollPlant Biotechnologies had 2 more articles in the media than Vicarious Surgical. MarketBeat recorded 3 mentions for CollPlant Biotechnologies and 1 mentions for Vicarious Surgical. CollPlant Biotechnologies' average media sentiment score of 0.96 beat Vicarious Surgical's score of 0.00 indicating that CollPlant Biotechnologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vicarious Surgical	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CollPlant Biotechnologies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

47.3% of Vicarious Surgical shares are owned by institutional investors. Comparatively, 21.7% of CollPlant Biotechnologies shares are owned by institutional investors. 11.1% of Vicarious Surgical shares are owned by company insiders. Comparatively, 9.6% of CollPlant Biotechnologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Vicarious Surgical presently has a consensus target price of $7.00, indicating a potential upside of 4,017.65%. CollPlant Biotechnologies has a consensus target price of $11.50, indicating a potential upside of 3,042.08%. Given Vicarious Surgical's higher possible upside, research analysts plainly believe Vicarious Surgical is more favorable than CollPlant Biotechnologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vicarious Surgical	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
CollPlant Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Vicarious Surgical has a net margin of 0.00% compared to CollPlant Biotechnologies' net margin of -683.68%. Vicarious Surgical's return on equity of -184.13% beat CollPlant Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vicarious Surgical	N/A	-184.13%	-112.50%
CollPlant Biotechnologies	-683.68%	-218.81%	-139.28%

Summary

Vicarious Surgical beats CollPlant Biotechnologies on 8 of the 15 factors compared between the two stocks.

How does Vicarious Surgical compare to Innovative Eyewear?

Innovative Eyewear (NASDAQ:LUCY) and Vicarious Surgical (NYSE:RBOT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, media sentiment, earnings and valuation.

1.0% of Innovative Eyewear shares are owned by institutional investors. Comparatively, 47.3% of Vicarious Surgical shares are owned by institutional investors. 1.7% of Innovative Eyewear shares are owned by insiders. Comparatively, 11.1% of Vicarious Surgical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Innovative Eyewear and Innovative Eyewear both had 1 articles in the media. Innovative Eyewear's average media sentiment score of 1.92 beat Vicarious Surgical's score of 0.00 indicating that Innovative Eyewear is being referred to more favorably in the media.

Company	Overall Sentiment
Innovative Eyewear	Very Positive
Vicarious Surgical	Neutral

Innovative Eyewear has a beta of 2.66, meaning that its stock price is 166% more volatile than the broader market. Comparatively, Vicarious Surgical has a beta of 1.75, meaning that its stock price is 75% more volatile than the broader market.

Vicarious Surgical has a consensus target price of $7.00, indicating a potential upside of 4,017.65%. Given Vicarious Surgical's stronger consensus rating and higher possible upside, analysts plainly believe Vicarious Surgical is more favorable than Innovative Eyewear.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innovative Eyewear	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Vicarious Surgical	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Vicarious Surgical has a net margin of 0.00% compared to Innovative Eyewear's net margin of -272.42%. Innovative Eyewear's return on equity of -83.37% beat Vicarious Surgical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innovative Eyewear	-272.42%	-83.37%	-76.02%
Vicarious Surgical	N/A	-184.13%	-112.50%

Innovative Eyewear has higher revenue and earnings than Vicarious Surgical. Innovative Eyewear is trading at a lower price-to-earnings ratio than Vicarious Surgical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innovative Eyewear	$2.66M	1.89	-$7.59M	-$1.69	N/A
Vicarious Surgical	N/A	N/A	-$63.22M	-$6.69	N/A

Summary

Innovative Eyewear beats Vicarious Surgical on 7 of the 13 factors compared between the two stocks.

How does Vicarious Surgical compare to Nanovibronix?

Vicarious Surgical (NYSE:RBOT) and Nanovibronix (NASDAQ:FEED) are both small-cap medical equipment companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, valuation, dividends and media sentiment.

Vicarious Surgical has a net margin of 0.00% compared to Nanovibronix's net margin of -923.20%. Nanovibronix's return on equity of -54.25% beat Vicarious Surgical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vicarious Surgical	N/A	-184.13%	-112.50%
Nanovibronix	-923.20%	-54.25%	-43.10%

Vicarious Surgical has a beta of 1.75, indicating that its share price is 75% more volatile than the broader market. Comparatively, Nanovibronix has a beta of 1.51, indicating that its share price is 51% more volatile than the broader market.

Vicarious Surgical currently has a consensus target price of $7.00, indicating a potential upside of 4,017.65%. Given Vicarious Surgical's stronger consensus rating and higher possible upside, research analysts clearly believe Vicarious Surgical is more favorable than Nanovibronix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vicarious Surgical	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Nanovibronix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

47.3% of Vicarious Surgical shares are owned by institutional investors. Comparatively, 16.4% of Nanovibronix shares are owned by institutional investors. 11.1% of Vicarious Surgical shares are owned by company insiders. Comparatively, 5.2% of Nanovibronix shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Nanovibronix has higher revenue and earnings than Vicarious Surgical. Nanovibronix is trading at a lower price-to-earnings ratio than Vicarious Surgical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vicarious Surgical	N/A	N/A	-$63.22M	-$6.69	N/A
Nanovibronix	$2.55M	1.29	-$18.18M	-$8.82	N/A

In the previous week, Nanovibronix had 1 more articles in the media than Vicarious Surgical. MarketBeat recorded 2 mentions for Nanovibronix and 1 mentions for Vicarious Surgical. Nanovibronix's average media sentiment score of 0.78 beat Vicarious Surgical's score of 0.00 indicating that Nanovibronix is being referred to more favorably in the news media.

Company	Overall Sentiment
Vicarious Surgical	Neutral
Nanovibronix	Positive

Summary

Vicarious Surgical beats Nanovibronix on 8 of the 14 factors compared between the two stocks.

How does Vicarious Surgical compare to Bluejay Diagnostics?

Bluejay Diagnostics (NASDAQ:BJDX) and Vicarious Surgical (NYSE:RBOT) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, dividends, earnings and analyst recommendations.

Bluejay Diagnostics is trading at a lower price-to-earnings ratio than Vicarious Surgical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bluejay Diagnostics	N/A	N/A	-$6.85M	-$11.63	N/A
Vicarious Surgical	N/A	N/A	-$63.22M	-$6.69	N/A

Vicarious Surgical has a consensus price target of $7.00, suggesting a potential upside of 4,017.65%. Given Vicarious Surgical's stronger consensus rating and higher possible upside, analysts plainly believe Vicarious Surgical is more favorable than Bluejay Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bluejay Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Vicarious Surgical	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Bluejay Diagnostics' return on equity of -144.27% beat Vicarious Surgical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bluejay Diagnostics	N/A	-144.27%	-115.00%
Vicarious Surgical	N/A	-184.13%	-112.50%

Bluejay Diagnostics has a beta of 0.82, meaning that its share price is 18% less volatile than the broader market. Comparatively, Vicarious Surgical has a beta of 1.75, meaning that its share price is 75% more volatile than the broader market.

18.5% of Bluejay Diagnostics shares are owned by institutional investors. Comparatively, 47.3% of Vicarious Surgical shares are owned by institutional investors. 6.1% of Bluejay Diagnostics shares are owned by insiders. Comparatively, 11.1% of Vicarious Surgical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Bluejay Diagnostics had 1 more articles in the media than Vicarious Surgical. MarketBeat recorded 2 mentions for Bluejay Diagnostics and 1 mentions for Vicarious Surgical. Bluejay Diagnostics' average media sentiment score of 0.44 beat Vicarious Surgical's score of 0.00 indicating that Bluejay Diagnostics is being referred to more favorably in the media.

Company	Overall Sentiment
Bluejay Diagnostics	Neutral
Vicarious Surgical	Neutral

Summary

Vicarious Surgical beats Bluejay Diagnostics on 8 of the 12 factors compared between the two stocks.

Get Vicarious Surgical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RBOT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RBOT vs. The Competition

Export

Metric	Vicarious Surgical	MED INSTRUMENTS Industry	Medical Sector	NYSE Exchange
Market Cap	$1.21M	$7.38B	$6.80B	$23.46B
Dividend Yield	N/A	1.25%	2.66%	4.07%
P/E Ratio	-0.02	50.35	27.48	31.97
Price / Sales	N/A	82.23	541.47	22.28
Price / Cash	N/A	26.23	48.53	25.04
Price / Book	0.02	7.47	10.97	4.85
Net Income	-$63.22M	$159.19M	$3.57B	$1.07B
7 Day Performance	-22.73%	1.02%	2.80%	2.23%
1 Month Performance	-79.01%	-3.31%	1.93%	3.44%
1 Year Performance	-97.68%	4.34%	36.49%	22.66%

Vicarious Surgical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RBOT Vicarious Surgical	1.7626 of 5 stars	$0.17 +18.1%	$7.00 +4,017.6%	-98.1%	$1.21M	N/A	N/A	210
PAVM PAVmed	2.8645 of 5 stars	$4.68 -4.7%	$56.00 +1,096.6%	-67.0%	$4.89M	$70K	N/A	90
CLGN CollPlant Biotechnologies	3.2157 of 5 stars	$0.35 +4.2%	$11.50 +3,167.0%	-74.6%	$4.87M	$2.37M	N/A	70	News Coverage Short Interest Decrease Gap Down
LUCY Innovative Eyewear	1.4925 of 5 stars	$0.77 +5.5%	N/A	-63.2%	$4.67M	$2.66M	N/A	9	Gap Up
FEED Nanovibronix	0.4989 of 5 stars	$0.64 -7.9%	N/A	N/A	$4.26M	$2.55M	N/A	20	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:RBOT) was last updated on 7/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vicarious Surgical (RBOT) Competitors

RBOT vs. PAVM, CLGN, LUCY, FEED, and BJDX

How does Vicarious Surgical compare to PAVmed?

Summary

How does Vicarious Surgical compare to CollPlant Biotechnologies?

Summary

How does Vicarious Surgical compare to Innovative Eyewear?

Summary

How does Vicarious Surgical compare to Nanovibronix?

Summary

How does Vicarious Surgical compare to Bluejay Diagnostics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RBOT vs. The Competition

Vicarious Surgical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vicarious Surgical (RBOT) Competitors

RBOT vs. PAVM, CLGN, LUCY, FEED, and BJDX

How does Vicarious Surgical compare to PAVmed?

Which has more volatility and risk, RBOT or PAVM?

Does the media favor RBOT or PAVM?

Do institutionals and insiders have more ownership in RBOT or PAVM?

Is RBOT or PAVM more profitable?

Which has stronger earnings and valuation, RBOT or PAVM?

Do analysts rate RBOT or PAVM?

Summary

How does Vicarious Surgical compare to CollPlant Biotechnologies?

Which has stronger earnings and valuation, RBOT or CLGN?

Which has more volatility & risk, RBOT or CLGN?

Does the media prefer RBOT or CLGN?

Do institutionals & insiders believe in RBOT or CLGN?

Do analysts rate RBOT or CLGN?

Is RBOT or CLGN more profitable?

Summary

How does Vicarious Surgical compare to Innovative Eyewear?

Do insiders & institutionals believe in LUCY or RBOT?

Does the media refer more to LUCY or RBOT?

Which has more risk & volatility, LUCY or RBOT?

Do analysts prefer LUCY or RBOT?

Is LUCY or RBOT more profitable?

Which has stronger valuation & earnings, LUCY or RBOT?

Summary

How does Vicarious Surgical compare to Nanovibronix?

Is RBOT or FEED more profitable?

Which has more risk & volatility, RBOT or FEED?

Do analysts rate RBOT or FEED?

Do insiders and institutionals believe in RBOT or FEED?

Which has preferable earnings & valuation, RBOT or FEED?

Does the media prefer RBOT or FEED?

Summary

How does Vicarious Surgical compare to Bluejay Diagnostics?

Which has better earnings and valuation, BJDX or RBOT?

Do analysts prefer BJDX or RBOT?

Is BJDX or RBOT more profitable?

Which has more risk & volatility, BJDX or RBOT?

Do insiders & institutionals hold more shares of BJDX or RBOT?

Does the media refer more to BJDX or RBOT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RBOT vs. The Competition

Vicarious Surgical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools